While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. Please watch the video at Investors.com - How To Buy Stocks ...

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it down for ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

Empaveli could achieve peak sales of $700 million by 2031, targeting C3G and IC-MPGN markets. Syfovre is expected to reach U.S. peak sales of $2 billion by 2030, driven by strong demand and ...

The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in commercial vial ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

“The third quarter was marked by continued progress, including growth in SYFOVRE vial demand and the positive Phase 3 VALIANT study results in C3G and IC-MPGN. While SYFOVRE net sales fell short ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

MoA International Fund earns a High Process Pillar rating. The largest contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...

Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of ...